/** blogpostTitle: OneSource Q1 FY27: Semaglutide scale-up lifts margins as capacity expansion stays on track blogpostSlug: onesource-q1 blogpostCoverImageUrl: null blogpostCoverImageDescription: An ultra-realistic corporate finance scene showing a clean desk with a laptop displaying a dashboard of quarterly performance metrics and charts: revenue and EBITDA rising year-on-year, an EBITDA margin gauge moving upward to 27.5%, and a simple capacity timeline graphic indicating a second sterile cartridge line commissioning in Q2 and a larger FY28 capacity expansion. The visuals should be generic with no company logos or text labels, set in a modern boardroom environment with neutral lighting. blogpostShortTitle: OneSource Q1FY27 semaglutide ramps, margins rise */

OneSource Q1 FY27: Semaglutide scale-up lifts margins as capacity expansion stays on track

OneSource Specialty Pharma opened FY27 with a quarter shaped by two clear themes: the commercial scale-up of semaglutide in key off-patent markets and a continuing build-out of its broader CDMO platform. For Q1 FY27, the company reported revenue of ₹4,490 million ($47.5 million), up 37$13.1 million), up 39% year-on-year and 34% quarter-on-quarter, while EBITDA margin expanded sharply to 27.5%.

Management attributed the margin lift largely to operating leverage from higher Drug Device Combination (DDC) revenue as semaglutide commercialisation accelerated. Adjusted PAT for the quarter was ₹637 million ($6.7 million), up 72% year-on-year. The company clarified that adjusted PAT excluded exceptional items and scheme-related intangible amortisation.

What drove the quarter

The operational narrative in Q1 FY27 was dominated by semaglutide. In the earnings call, the CEO highlighted Canada as the largest off-patent semaglutide market currently open globally and stated that all three approvals in Canada are with OneSource, with two partners already launched. In India, management said that many customers launched on day one and that as of June 26, more than 40% of the generic pen market sold in India was manufactured at OneSource’s site.

The company also pointed to breadth in customer engagement. In its investor presentation, it reported 11 new wins, 70 plus active RFPs in the pipeline, six new logos taking total customers to 80 plus, and nine launches during the quarter. The same update also referenced continued quality execution with 12 regulatory inspections and customer audits, and noted EU GMP and TGA GMP outcomes across two sites.

Financial summary (Q1 FY27)

Capacity expansion: the near-term execution test

A major element of the OneSource investment case is whether capacity comes online in time to support growing demand. The company reiterated that its DDC capacity expansion is progressing as planned. The investor presentation stated that Phase 1 of the expansion is near completion, with a new cartridge line scheduled to commercialise in Q2 and expected to double total sterile production days. It also said Phase 2 Line 1 is to be installed in FY27 and is intended to triple sterile production days for FY28.

On the earnings call, management reinforced that the second cartridge line will be commercialised in the current quarter, and discussed how additional capacity is expected to help onboard new customers. The CEO also said the company had previously been constrained in adding new customers due to a supply gap, and that the process of customer addition has already started.

A recurring investor concern has been customer-specific volatility in semaglutide supply chains. Management addressed this by referring to a temporary disruption announced by Dr. Reddy’s and said that the company’s available capacities remain full due to its diversified customer base across markets and contract types. While that provides some near-term comfort, it also underscores the importance of commissioning new lines smoothly so demand can be met without over-reliance on any single customer’s timeline.

The company also disclosed progress on capital allocation. The investor presentation noted that 80% of the announced $100 million capex program is fully committed. In the Q&A, management reiterated this and suggested that any future biologics expansion capex would likely be incremental and materially lower than what has been invested in DDC.

Biologics: building a longer runway beyond FY28

Beyond GLP-1 driven DDC momentum, OneSource is positioning biologics as a growth pillar that can scale beyond FY28. The investor presentation described an integrated biologics platform with both drug substance and drug product capabilities. It outlined current and planned capacities across systems: microbial capacity of 1 KL with an additional 5 KL planned, and mammalian capacity of 4 KL with an additional 4 KL planned.

The company’s biosimilars narrative gained visibility with the announced partnership with Formycon. The presentation framed this as an integrated DS plus DP collaboration supported by industry tailwinds such as evolving regulatory pathways, supply chain de-risking and upcoming patent expiries. In the earnings call, management said the RFP funnel is at an all-time high and roughly 4x versus just over a year ago, spanning innovators, biosimilars and animal health.

A key detail from management commentary is timing. The CEO stated that biologics programs often start with development-stage revenues under MSAs and convert into commercial revenues later, and specifically discussed that many of these customers could contribute commercial revenue from FY29 onwards. For investors, this makes biologics less about immediate quarterly volatility and more about visible pipeline conversion, capacity planning, and sustained customer retention.

Base business: injectables and softgels remain in investment mode

OneSource continues to invest in expanding capabilities across its base platforms. On injectables, management reiterated its focus on scarcity-oriented manufacturing and stated it is adding new capabilities including pre-filled syringes and significantly expanding lyophilisation capacity. The CEO said a shutdown at one sterile injectable site will start in Q2 and continue between Q2 and Q3 to enable these additions, and that the capacity addition is expected to contribute meaningfully toward FY28.

Softgels, meanwhile, are in a transition from a more captive, IP-led setup to a broader CDMO offering. In response to questions on growth and utilisation, management said customer tech transfers from other sites take time and indicated it expects the new capacity to be taken over the next 12 to 15 months. It also stated that, because the current site cannot expand further, it has already initiated a process to start a greenfield.

Outlook: reaffirmed FY28 targets

OneSource reaffirmed its FY28 outlook of $400 million organic revenue and a steady state EBITDA margin of 40%. The investor presentation also stated a targeted ROCE above 50%, with ROCE calculated excluding goodwill and scheme intangibles and excluding capital investment in progress.

For the rest of FY27, the milestones that will likely matter most are operational: commissioning and ramping of the second cartridge line in Q2, continued progress on additional DDC lines referenced by management, and clarity on how quickly the biologics funnel converts into signed work. Q1 FY27 provided evidence of operating leverage when DDC volumes move up. The next phase is to prove that capacity expansion and execution discipline can keep pace with demand.